Table 6.

Summary of the pharmacokinetic parameters for conjugated taxanes, unconjugated paclitaxel and carboplatin after cycle 1 and cycle 4 administration of CT-2103 at 135 mg/m², 175 mg/m² or 225 mg/m² and carboplatin (AUC 6)

Drug Cycle	Conjugated Taxanes (mg/m2)						Unconjugated Paclitaxel (mg/m2)						Carboplatin
	1			4			1			4			1	4
Dose	135	175	225	135	175	225	135	175	225	135	175	225	*	*
Cases	3	5	3	5	2	1	3	5	3	4	2	1	11	8
Cmax
mean	87.0	84.7	130.7	65.4	85.2	104.0	0.32	0.42	0.47	0.29	0.29	0.50	42.4	33.3
SD	11.5	13.2	25.7	4.6	29.4		0.18	0.21	0.14	0.05	0.04		8.93	11.1
AUC
mean	953	1006	2216	901	1455	1995	4.07	5.18	7.19	4.16	4.05	8.79	103	85.3
SD	361	229	588	139	846		1.09	3.19	0.76	0.35	1.62		19.4	19.7
CL
mean	154	180	107	153	145	113							6.50	7.12
SD	50	37	33	25	84								1.60	2.21
t½,z
mean	89.2	55.3	57.7	6.75	9.05	11.3	25.7	16.1	13.4	13.9	15.2	13.9	3.16	2.88
SD	58.9	21.5	12.3	1.33	3.14		9.01	3.97	1.86	2.21	0.07		0.98	0.63
Vz
mean	21.6	14.5	9.25	1.47	1.70	1.83							29.3	28.5
SD	19.7	7.60	4.65	0.23	0.45								10.6	7.09
Vss
mean	2.66	2.79	2.06	1.81	1.94	1.92							16.1	18.0
SD	1.86	0.82	0.40	0.12	0.62								3.53	4.76
fe°
mean	6.01	6.40	5.83				1.27	1.97	1.80				64.0
SD	1.67	1.89	0.85				0.22	0.51	0.21				14.1
CLR
mean	9.18	12.5	7.31				508	884	622
SD	0.79	5.39	2.89				112	403	94.6